The Worldwide Market for Liquid Biopsy, 6th Edition

Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.

Key applications of liquid biopsy testing in clinical oncology include:

1. Early Detection and Diagnosis/Screening:
   • Identifying cancer at an early stage.
2. Alternative Testing Method:
   • When tissue biopsy is challenging or impossible.
   • When the primary site of metastatic disease is unknown.
3. Therapy Personalization and Monitoring:
   • Molecular characterization to select optimal therapy.
   • Monitoring treatment efficacy and adjusting therapy in case of resistance.
4. Disease Monitoring:
   • Observing disease progression, tumor evolution, residual disease.
   • Early detection of recurrence.
5. Prognosis of Disease:
   • Assessing the likely course and outcome of the disease.

The liquid biopsy market is experiencing significant changes, and The Worldwide Market for Liquid Biopsy, 6^th Edition from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. It covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.

Key Market Segments:

• By Region:
  • North America
  • Europe
  • Asia
  • Rest of World
• By Type of Liquid Biopsy:
  • CTC-based Liquid Biopsy
  • ctDNA-based Liquid Biopsy
  • EV and Exosome-based Liquid Biopsy
  • Multi-Analyte-based Liquid Biopsy
  • Other Analytes Liquid Biopsy
• By Type of Cancer:
  • Breast
  • Lung
  • Colorectal
  • Ovarian
  • Prostate
  • Pan-Cancer
  • Other Cancers
• R&D and Selected Tests:
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected CTC-based Liquid Biopsy Tests in 2023
  • Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023

The growing acceptance of liquid biopsy, even during the COVID-19 pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.

The report also profiles key companies in the liquid biopsy market. These include:

• Adaptive Biotechnologies
• Agena Bioscience, Inc.
• Angle, PLC
• Aspira Women’s Health
• Biocartis Group Nv
• Biocept, Inc. (closed)
• Biodesix
• Cellmax Life
• Circulogene
• Diacarta, Inc.
• Epic Sciences
• Epigenomics AG (closed)
• Exact Sciences
• Exosome Diagnostics, Inc.
• Foundation Medicine, Inc. (Roche)
• Freenome, Inc.
• Gilupi Gmbh
• Grail (Illumina)
• Guardant Health, Inc.
• Hologic
• Lunglife AI (Formerly Cynvenio Biosystems)
• Menarini-Silicon Biosystems, SPA
• Myriad Genetics, Inc.
• Natera, Inc.
• Neogenomics Laboratories, Inc.
• Oncocyte Corporation
• Oncodna S.A.
• Personal Genome Diagnostics
• Qiagen N.V.
• Cell-Free DNA Technologies
• Ctc Technologies
• Exosome And Mirna Technologies
• Resolution Biosciences (Agilent)
• Roche Diagnostics
• Sysmex-Inostics, Inc.
• Tempus
• Volitionrx